Abstract
α-Glucosidase and α-amylase are the two main glycosidases that participate in the metabolism of carbohydrates. Inhibitors of these two enzymes are considered an important medical treatment for carbohydrate uptake disorders, such as diabetes and obesity. Microbes are an important source of constituents that have the potential to inhibit glycosidases and can be used as sources of new drugs and dietary supplements. For example, the α-glucosidase inhibitor acarbose, isolated from Actinoplanes sp., has played an important role in adequately controlling type 2 diabetes, but this class of marketed drugs has many drawbacks, such as poor compliance with treatment and expense. This demonstrates the need for new microorganism-derived resources, as well as novel classes of drugs with better compliance, socioeconomic benefits, and safety. This review introduces the literature on microbial sources of α-glucosidase and α-amylase inhibitors, with a focus on endophytes and marine microorganisms, over the most recent 5 years. This paper also reviews the application of glycosidase inhibitors as drugs and dietary supplements. These studies will contribute to the future development of new microorganism-derived glycosidase inhibitors.
Introduction: The Search for New Starch Blockers
The global prevalence of type 2 diabetes and obesity has created an urgent need for effective "starch blockers." Two enzymes, α-glucosidase and α-amylase, are the primary targets; by inhibiting them, we can slow down the breakdown of complex carbohydrates into glucose, thereby preventing dangerous postprandial (post-meal) blood sugar spikes.
While drugs like acarbose (isolated from Actinoplanes sp.) have been used for decades, they are far from perfect. Patients often report poor compliance due to gastrointestinal side effects and high costs. Furthermore, traditional environmental sources for these inhibitors are becoming "exhausted," leading to a scarcity of new lead compounds. This review, published in Frontiers in Microbiology, synthesizes the last five years of research (2018–2022) into microbial metabolites that act as glycosidase inhibitors, shifting focus toward "extremophiles" found in marine environments and inside plant tissues (endophytes).
Methodology
The authors performed a systematic consolidation of peer-reviewed literature from major databases including PubMed, Google Scholar, and Web of Science. The review categorizes findings based on:
- Microbial Source: Distinguishing between bacterial (e.g., Actinomycetes, Bacillus, Lactobacillus) and fungal sources (e.g., Aspergillus, Penicillium, mushrooms).
- Environment: Highlighting the specific advantages of marine-derived and endophytic (symbiotic with plants) organisms.
- Chemical Structure: Identifying the specific metabolites (phenols, peptides, xanthones, etc.) responsible for inhibitory activity.
Chemical Diversity Beyond Sugars
One of the most significant insights from recent research is the shift away from general soil microbes. The deep-ocean interior and the internal tissues of medicinal plants (like Murraya koenigii) are proving to be goldmines for unique chemical scaffolds that soil microbes simply don't produce. While many traditional inhibitors are sugar-like (iminosugars), recent discoveries include diverse non-sugar structures like the isobutylhexapeptide TXS-2 and various meroterpenoids.
This structural diversity, illustrated by compounds such as those shown above, may help in designing drugs with fewer side effects. These inhibitors also show multi-functional potential in antiviral therapy (disrupting viral envelope glycoproteins) and as pharmacological chaperones for lysosomal storage diseases.
Key Results and Potency Benchmarks
Recent studies have identified several highly potent leads:
- Bacterial Potency: Streptomyces costaricanus EBL.HB6 showed a highly potent α-glucosidase IC50 of 9.59 mg/ml. In the marine sector, Streptomyces sp. S2A yielded compounds with IC50 values around 21 μg/ml for both enzymes.
- Fungal Excellence: A new meroterpenoid (Compound 14) from the marine fungus Aspergillus terreus demonstrated significant α-glucosidase inhibition with an IC50 of 24.8 μM.
- In Vivo Validation: Several studies moved beyond the test tube. For instance, the compound OMC from Amycolatopsis thermoflava successfully inhibited blood sugar increases in Wistar rats, proving that these microbial metabolites can survive the complex environment of a living digestive system.
Limitations and Future Outlook
Despite the promise of these new metabolites, several hurdles remain:
- Structural Gaps: Some of the most promising new leads, such as the C7N aminocyclitol from Arthrobacter enclensis, have not yet had their full chemical structures solved.
- Clinical Translation: While the in vitro and animal data are robust, there is a lack of human clinical trial data for these specific newly discovered metabolites.
- Industrial Scaling: Transitioning from a small-scale lab culture of a rare marine microbe to industrial-scale production remains a significant engineering challenge that requires further optimization of cultivation conditions.
The authors propose the creation of a centralized, open-access database for microbial glycosidase inhibitors to accelerate drug discovery and industrial scaling, ensuring these "extremophile" discoveries can eventually reach the patients who need them.
Summary updated